5,6,11,12,17,18-hexahydrocyclononatriindole has been researched along with tamoxifen in 1 studies
Studies (5,6,11,12,17,18-hexahydrocyclononatriindole) | Trials (5,6,11,12,17,18-hexahydrocyclononatriindole) | Recent Studies (post-2010) (5,6,11,12,17,18-hexahydrocyclononatriindole) | Studies (tamoxifen) | Trials (tamoxifen) | Recent Studies (post-2010) (tamoxifen) |
---|---|---|---|---|---|
5 | 0 | 0 | 20,630 | 2,227 | 6,256 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bjeldanes, LF; Chang, YC; Feng, C; Firestone, GL; Riby, JE; Schaldach, CM | 1 |
1 other study(ies) available for 5,6,11,12,17,18-hexahydrocyclononatriindole and tamoxifen
Article | Year |
---|---|
The major cyclic trimeric product of indole-3-carbinol is a strong agonist of the estrogen receptor signaling pathway.
Topics: Animals; Binding, Competitive; Cell Division; Electrophoresis, Polyacrylamide Gel; Humans; Indoles; Mice; Models, Molecular; Receptors, Aryl Hydrocarbon; Receptors, Estrogen; Signal Transduction; Tamoxifen; Transcriptional Activation; Tumor Cells, Cultured | 2000 |